Immunicum is listed on NASDAQ OMX First North Premier under the ticker IMMU.
A unique approach to apply allogeneic dendritic cells in immuno-oncology.Read more
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma20 Jun 2017
Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX®12 Jun 2017
- 30 May 2017
Developing innovative cancer immunotherapies
We are on a journey towards the world’s first patient unique, off-the-shelf cancer treatment. Get to know the technology that will take us there.Learn more